Stockreport

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapiesLed by nontuberculous mycobacteria (NTM) expert Dr. Kevin Wint [Read more]